CMV and End Organ Disease

The challenge with CAR T patients is that unlike a logianic transplant, we have not routinely performed CMVPCR surveillance when the CAR T program started. So cases of CMV reactivation would not really get diagnosed until they reached the end organ disease stage. This was one of my fileship projects at MD Anderson. We had 230 patients who received CAR T cell and I believe the overwhelming majority of these were CP 19 without clinically significant CMV infection.